Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
Pfizer: Transforming UK health, one patient at a time
Pfizer is committed to supporting healthcare quality improvement initiatives and research. In 2016, Pfizer spent over £250 million supporting research and development carried out in the UK and contributed to 162 collaborations with universities, pharmaceutical companies, industries and others. Through such collaborations and sharing knowledge, skills and expertise, Pfizer aim to improve the health and lives of people in the UK and around the world.
Complementing Pfizer’s long-standing commitment to innovative research and development, Pfizer also supports healthcare organisations, academic institutions, charities, patient organisations, community organisations, and professional societies through donations. Pfizer also actively supports the scientists of tomorrow, through the National Apprenticeship Programme, its undergraduate placement scheme and through various STEM (Science Technology Engineering and Mathematics) and SIP (Science Industry Partnership) activities.
Univadis® is a medical digital platform used and appreciated by more than 3 million HCPs worldwide. Univadis® accompanies HCPs in their everyday practice and development, by providing easy access to clinical literature digests, decision-support tools, medical quizzes and succinct eLearning modules.
Univadis® is committed to delivering impartial and accurate health information to HCPs. Our professional editorial staff is responsible for the curation, creation, and maintenance of the content. Our goal is to continually discover the best means to help solve medical information overload and provide a unique resource for HCPs to remain current in medicine and continually improve their practice.
Novo Nordisk Obesity Corporate Narrative
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes and obesity care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions such as haemophilia and growth disorders.
A heritage of driving change
Going beyond medicine, we also recognise that to improve care for people living with obesity, change needs to happen across society – from prevention and defeating stigma to enacting the right policies and using the right treatments when needed.